GILD - Gilead Sciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
68.02
+0.42 (+0.62%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close67.60
Open67.59
Bid67.90 x 800
Ask68.02 x 1000
Day's Range67.34 - 68.49
52 Week Range63.76 - 89.54
Volume5,422,767
Avg. Volume7,294,051
Market Cap88.444B
Beta1.35
PE Ratio (TTM)25.87
EPS (TTM)2.63
Earnings DateJul 24, 2018 - Jul 30, 2018
Forward Dividend & Yield2.28 (3.49%)
Ex-Dividend Date2018-06-14
1y Target Est86.00
Trade prices are not sourced from all markets
  • The FDA Is Trying To 'Shame' Celgene, Gilead — Here's Why It Won't Work
    Investor's Business Daily3 days ago

    The FDA Is Trying To 'Shame' Celgene, Gilead — Here's Why It Won't Work

    Celgene toppled to a four-year low Thursday after it appeared on a list from the FDA attempting to "shame" drugmakers working to block generic competition.

  • Sangamo Therapeutics Stock History
    Motley Fool3 days ago

    Sangamo Therapeutics Stock History

    After decades of research into gene editing, this biotech company could be on the cusp of developing game-changing new treatments for rare diseases.

  • Taking Stock of Gilead Sciences’ Key Developments
    Market Realist3 days ago

    Taking Stock of Gilead Sciences’ Key Developments

    During the first quarter, Gilead Sciences (GILD) entered into a scientific collaboration with Verily Life Sciences to identify and better understand the immunological basis of three common, serious inflammatory diseases—rheumatoid arthritis, inflammatory bowel disease, and lupus-related diseases—by making use of Verily’s Immunoscape platform.

  • 3 High-Yield Stocks With Virtual Monopolies
    Motley Fool3 days ago

    3 High-Yield Stocks With Virtual Monopolies

    This trio of high-yield stocks offers dividend investors a lock on key markets with virtual monopolies driving big dividend payments.

  • Gilead Sciences’ Cash Flows, Valuations, and Price Performance
    Market Realist3 days ago

    Gilead Sciences’ Cash Flows, Valuations, and Price Performance

    Gilead Sciences (GILD) stock has corrected 9.6% since the start of 2018 to close at $66.99 on May 15. In comparison, Johnson & Johnson (JNJ), Pfizer (PFE), and Merck & Co. (MRK) have returned -9.5%, -2.1%, and 5.3%, respectively.

  • A Look at Gilead Sciences’ Financial Performance
    Market Realist3 days ago

    A Look at Gilead Sciences’ Financial Performance

    Gilead Sciences’ (GILD) total revenues decreased from $6.5 billion in Q1 2017 to $5.1 billion in Q1 2018, primarily due to lower product sales. The company earns a small part of its revenues from royalty, contract, and other sources. While product sales were $6.3 billion in Q1 2017 and $5 billion in Q1 2018, royalty, contract, and other revenues were $128 million in Q1 2017 and $87 million in Q1 2018.

  • Gilead Sciences’ Product Performance: A Mixed Bag in Q1 2018
    Market Realist4 days ago

    Gilead Sciences’ Product Performance: A Mixed Bag in Q1 2018

    In the first quarter, Gilead Sciences’ (GILD) total product sales decreased to $5 billion from $6.3 billion in the first quarter of 2017. For fiscal 2018 and fiscal 2019, it’s expected to report total revenues of $20.8 billion and $21.1 billion, respectively.

  • Gilead Sciences Stock: How Much Upside Do Analysts Expect?
    Market Realist4 days ago

    Gilead Sciences Stock: How Much Upside Do Analysts Expect?

    Gilead Sciences (GILD) is a research-based biopharmaceutical company focused on discovering, developing, and bringing to market innovative medicines for life-threatening diseases. Gilead released its first-quarter earnings on May 4. Of the 26 analysts covering Gilead Sciences stock in May, 16 of them have given the stock a “buy” or higher rating, and ten have given it a “hold.” The mean rating for the stock is 2.2 with a target price of $85.81, which implies an upside potential of 27.2% over its closing price of $66.99 on May 15.

  • Breakout Watch: Biotech Stock With 172% Growth Enters Buy Zone
    Investor's Business Daily4 days ago

    Breakout Watch: Biotech Stock With 172% Growth Enters Buy Zone

    Leading biotech stock and IBD 50 member Ligand Pharmaceuticals is in a buy zone after reporting 172% earnings growth.

  • Business Wire5 days ago

    U.S. Food and Drug Administration Approves Expanded Indication for Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents

    Gilead Sciences, Inc. (GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada® (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)—in combination with safer sex practices—to reduce the risk of sexually acquired HIV-1 in at-risk adolescents. The safety and efficacy profile of Truvada for HIV prevention in uninfected adults, a strategy called pre-exposure prophylaxis (PrEP), is well established, and Truvada for PrEP was first approved for use in adults in 2012. The addition of the adolescent indication is based on a study in HIV-negative individuals 15 to 17 years of age.

  • Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline
    Business Wire5 days ago

    Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline

    Kite, a Gilead Company (GILD), today announced it has leased a new facility in the Netherlands to engineer cell therapies in Europe. The 117,000 square-foot site in Hoofddorp (SEGRO Park Amsterdam Airport) will enable Kite to efficiently manufacture and deliver its cell therapies to people living with cancer in Europe and will provide more than 300 new jobs when fully operational in 2020. The facility will engineer and produce innovative cell therapies, including axicabtagene ciloleucel, a Chimeric Antigen Receptor T cell (CAR T) therapy that is currently under review by the European Medicines Agency and which is approved in the United States as Yescarta®.

  • MarketWatch6 days ago

    Why Trump’s drug-price pitch makes no sense

    Donald Trump’s speech on drug prices on Friday was no surprise — it was his usual mishmash of pseudo-populist nonsense, obscuring the standard-issue corporatist Republican agenda he reverts to when he knows nothing, which is most of the time. The speech abandoned one of the few more-or-less populist campaign promises the president made in 2016 — to have Medicare begin negotiating over drug prices, reversing a law his party passed specifically to maximize drug-company profits.

  • CNBC9 days ago

    Cramer says it's 'very hard to put a price on' lifesaving drugs

    President Trump on Friday is set to release a plan aimed at cutting prescription drug costs. But Jim Cramer argues some drugs may be worth it.

  • Cramer says it's 'very hard to put a price on' lifesaving drugs
    CNBC9 days ago

    Cramer says it's 'very hard to put a price on' lifesaving drugs

    President Trump on Friday is set to release a plan aimed at cutting prescription drug costs. But Jim Cramer argues some drugs may be worth it.

  • CNBC10 days ago

    Cramer vets biotech giants Biogen, Celgene, Gilead and Regeneron for positive prospects

    Jim Cramer examines "the four horsemen of biotech" to see if their weakening stocks can regain momentum.

  • Analysts’ Recommendations for Regeneron Pharmaceuticals in May
    Market Realist10 days ago

    Analysts’ Recommendations for Regeneron Pharmaceuticals in May

    In April 2018, the FDA accepted for priority review Regeneron Pharmaceuticals (REGN) and Sanofi’s (SNY) Biologics License Application (or BLA) for cemiplimab for the treatment of individuals with metastatic CSCC (cutaneous squamous cell carcinoma) or individuals with locally advanced CSCC who cannot be treated with surgery. In September 2017, the FDA granted cemiplimab Breakthrough Therapy designation status for the treatment of metastatic CSCC. The FDA provided a Prescription Drug User Fee Act action date of October 28, 2018.

  • Business Wire11 days ago

    Harish Manwani Joins Gilead Sciences’ Board of Directors

    Gilead Sciences, Inc.  announced today that Harish M. Manwani has been appointed to the company’s Board of Directors.

  • Why Bristol-Myers Squibb Stock Crashed in April
    Motley Fool11 days ago

    Why Bristol-Myers Squibb Stock Crashed in April

    The company's stock hasn't been this cheap in years. Time to buy?

  • 3 Stocks That Turned $10,000 Into $1 Million
    Motley Fool11 days ago

    3 Stocks That Turned $10,000 Into $1 Million

    These three biotech stocks delivered monster returns over the past couple of decades. Here's how.

  • Why Sangamo Therapeutics Stock Dropped Today
    Motley Fool12 days ago

    Why Sangamo Therapeutics Stock Dropped Today

    Valuing early-stage biotechs is hard.

  • Business Wire12 days ago

    Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 16

    Gilead Sciences, Inc. (GILD) today announced that Robin L. Washington, Gilead’s Executive Vice President and Chief Financial Officer, and John McHutchison, Gilead’s Chief Scientific Officer and Head of Research & Development, will participate in a fireside chat at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas on Wednesday, May 16 at 9:20 a.m. Pacific Time. The audio portion of the fireside chat will be accessible live through the company’s Investors page at www.gilead.com/investors.

  • Wall Street Recommendations for Exelixis in May 2018
    Market Realist13 days ago

    Wall Street Recommendations for Exelixis in May 2018

    As per the terms of the agreement, Exelixis and Invenra will jointly discover and develop antibodies with the help of Invenra’s B-Body technology platform, which allows high-throughput screening along with in vitro and in vivo preclinical characterization for the development of potential therapeutic candidates. According to the terms of the agreement, Exelixis will lead preclinical trials, manufacturing, the clinical development of both single-regimen and combination-regimen therapies along with regulatory filling and commercialization. Also under this collaboration, Exelixis and Invenra plan to conduct up to six discovery projects.

  • ACCESSWIRE13 days ago

    Could Unknown Orgenesis (ORGS) Be The Next Double Or Triple In The Cell Therapy Space?

    Many investors missed the trend when Chinese pharmaceutical companies got hot. Many of these stocks are up 3-fold or more in the last year as Chinese biotechnology companies have played catch-up to U.S. companies in the booming cell therapy market. As a result, developers are turning to specialized contract development manufacturing organizations (CDMOs).

  • The Zacks Analyst Blog Highlights: BP, Gilead, Enterprise Products and Colgate
    Zacks13 days ago

    The Zacks Analyst Blog Highlights: BP, Gilead, Enterprise Products and Colgate

    The Zacks Analyst Blog Highlights: BP, Gilead, Enterprise Products and Colgate

  • How Did Exelixis Perform in 1Q18?
    Market Realist16 days ago

    How Did Exelixis Perform in 1Q18?

    In 1Q18, Exelixis (EXEL) generated revenues of $212.3 million yesterday, compared to $80.89 million in 1Q17. In 1Q18, Exelixis witnessed ~77% growth on a quarter-over-quarter basis.